Immunologie des tumeurs et Immunothérapie

Présentation du laboratoire

Le laboratoire d'immunologie des tumeurs et immunothérapie contre le cancer a deux grands thèmes de recherche. Le premier est l'immunologie des tumeurs et l'immunothérapie contre le cancer et le second est le rôle de la traduction d'ARNm dans la présentation antigénique. Ces thèmes regroupent des études sur le microbiote intestinal et l'inflammation sur les tumeurs, l'immunothérapie personnalisée par des anticorps monoclonaux ou encore sur la cross présentation au CMH de classe I sur les peptides antigéniques. Ces recherches portent sur une meilleure compréhension de l'immunologie chez les patients atteints de cancer et d'améliorer les traitements personnalisés afin de mieux lutter contre cette maladie. Ces travaux en partenariats avec de nombreux partenaires industriels ont déjà permis la mise en oeuvre de 6 brevets.

Les 20 dernières publications

Titre Auteurs Date de publication Source
Crizotinib-induced immunogenic cell death in non-small cell lung cancer Laurence Zitvogel 01/12/2019 Nature Communications
Imaging-guided precision medicine in glioblastoma patients treated with immune checkpoint modulators: research trend and future directions in the field of imaging biomarkers and artificial intelligence F. L. Besson, Laurent Dercle 01/12/2019 EJNMMI Research
Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials? Aurélien Marabelle 01/11/2019 Annals of oncology : official journal of the European Society for Medical Oncology
Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade Aurélien Marabelle 23/10/2019 Science Translational Medicine
Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics Aurélien Marabelle, Amelie Bigorgne, Laurent Dercle 01/10/2019 European Journal of Nuclear Medicine and Molecular Imaging
Focus on Recommendations for the Management of Non-small Cell Lung Cancer Lambros Tselikas 15/09/2019 CardioVascular and Interventional Radiology
Interferon-γ induces cancer cell ferroptosis Laurence Zitvogel 01/09/2019 Cell Research
Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy Laurent Dercle 01/09/2019 European Journal of Cancer
Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity Laurence Zitvogel 01/09/2019 Nature medicine
A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation Lisa Derosa 15/08/2019 Angiogenesis
The role of multimodal imaging in guiding resectability and cytoreduction in pancreatic neuroendocrine tumors: focus on PET and MRI Laurent Dercle 15/07/2019 Abdominal Radiology
Trial watch: dietary interventions for cancer therapy Gladys Ferrere, Laurence Zitvogel 03/07/2019 OncoImmunology
Hyperprogression during immunotherapy: do we really want to know? Aurélien Marabelle 01/07/2019 Annals of Oncology
Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation Laurent Dercle 01/07/2019 European Journal of Cancer
Prevalence of human herpesviruses in biliary fluid and their association with biliary complications after liver transplantation Conrad Rauber 27/06/2019 BMC Gastroenterology
Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy Aurélien Marabelle 01/06/2019 American Journal of Ophthalmology
Anti–CTLA-4 immunotherapy does not deplete Foxp3<sup>þ</sup> regulatory T cells (Tregs) in human cancers—letter Aurélien Marabelle, Sandrine Susini 01/06/2019 Clinical Cancer Research
Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors Aurélien Marabelle 01/06/2019 Clinical Cancer Research
T-cell bispecific antibodies in node-positive breast cancer: Novel therapeutic avenue for MHC class i loss variants Caroline Flament, Meriem Messaoudene, Nicolas Jacquelot, ... 01/06/2019 Annals of Oncology
Anticancer effects of anti-CD47 immunotherapy in vivo Laurence Zitvogel 04/03/2019 OncoImmunology